Asherman's syndrome: a critique and current review
- PMID: 4725610
- DOI: 10.1016/s0015-0282(16)39918-6
Asherman's syndrome: a critique and current review
Abstract
PIP: Asherman's syndrome is described in today's context. Meaningful literature as it relates to the description and management of this entity is reviewed, and the forms of treatment used at the Hospital of the University of Pennsylvania or at the Philadelphia General Hospital are presented. Asherman's syndrome describes a variable amount of destruction of the endometrial cavity, diminished menstrual flow, infertility, and repeated pregnancy loss. The incidence of Asherman's syndrome was believed to be low, but Eriksen reported a 20-25% incidence of intrauterine adhesions of some degree in all patients treated with a dilatation and curettage within 2 months after delivery. The number of cases of Asherman's syndrome reported by other authors is unusually high, and a table of inferred incidence and therapeutic approaches is included. The main symptoms of Asherman's syndrome are infertility, secondary amenorrhea, cyclic painful hypoamenorrhea, menstrual irregularities, and habitual abortion. 11 patients with Asherman's syndrome presenting as intrauterine distortion and diminished menstrual flow were treated at the Department of Obstetics and Gynecology of the University of Pennsylvania, at the Hospital of the University of Pennsylvania, or at the Philadelphia General Hospital during the interval between July 19678 and June 1972. The patients ranged in age from 22-37. 6 were referred for infertility, and 5 were diagnosed during the course of delivery of primary care. The therapeutic regimes which were used for most of these patients are listed in a table. The approach consisted of careful sounding of the uterine cavity, followed by dilatation and curettage with histologic examination. A pediatric Foley catheter was inserted into the uterine cavity and the bag was filled to a 3-ml volume. Conjugated estrogens were given at dosages of 5.0-7.5 mg daily in divided doses. The estrogen dose was increased in instances of breakthrough bleeding. Broad-spectrum antibiotics were initiated preoperatively in most cases. The Foley catheter was removed after 5-7 days. Antibiotics were continued for a week to 10 days, and the estrogens were continued for 21 days. It was possible to reestablish normal menstrual patterns in 6 of the 7 women with severe disease. Pregnancies were established in 4 of these patients. There were 2 spontaneous abortions. In patients with moderate disease, a return to normal menstrual pattern occurred in all instances, but only 2 became pregnant. 1 pregnancy went to term, and the other is still in progress.
Similar articles
-
Asherman's syndrome.Obstet Gynecol. 1970 Dec;36(6):922-8. Obstet Gynecol. 1970. PMID: 5487746 No abstract available.
-
Amenorrhea secondary to puerperal curettage (Asherman's syndrome).Am J Obstet Gynecol. 1972 May 15;113(2):150-7. doi: 10.1016/0002-9378(72)90764-8. Am J Obstet Gynecol. 1972. PMID: 5025872 No abstract available.
-
Hysteroscopic adhesiolysis for patients with Asherman's syndrome: menstrual and fertility outcomes.Reprod Med Biol. 2013 May 5;12(4):159-166. doi: 10.1007/s12522-013-0149-x. eCollection 2013 Oct. Reprod Med Biol. 2013. PMID: 29662367 Free PMC article.
-
Fertility after contraception or abortion.Fertil Steril. 1990 Oct;54(4):559-73. doi: 10.1016/s0015-0282(16)53808-4. Fertil Steril. 1990. PMID: 2209874 Review.
-
[Asherman's syndrome I--history, prevalence, histopathology, classification, ethiology, symtomatology and investigations].Ceska Gynekol. 2010 Dec;75(6):492-8. Ceska Gynekol. 2010. PMID: 27534003 Review. Czech.
Cited by
-
Association of intrauterine synechiae with pituitary gonadotrophin pulse patterns: A pilot study.PLoS One. 2023 Dec 15;18(12):e0289075. doi: 10.1371/journal.pone.0289075. eCollection 2023. PLoS One. 2023. PMID: 38100407 Free PMC article.
-
CXCL12 Promotes Stem Cell Recruitment and Uterine Repair after Injury in Asherman's Syndrome.Mol Ther Methods Clin Dev. 2017 Jan 11;4:169-177. doi: 10.1016/j.omtm.2017.01.001. eCollection 2017 Mar 17. Mol Ther Methods Clin Dev. 2017. PMID: 28345002 Free PMC article.
-
Extracellular Vesicles Derived from Mesenchymal Stem Cells as Cell-Free Therapy for Intrauterine Adhesion.Int J Stem Cells. 2023 Aug 30;16(3):260-268. doi: 10.15283/ijsc21177. Epub 2023 Jun 30. Int J Stem Cells. 2023. PMID: 37385632 Free PMC article. Review.
-
Bone Marrow-Derived Stem Cell (BMDSC) transplantation improves fertility in a murine model of Asherman's syndrome.PLoS One. 2014 May 12;9(5):e96662. doi: 10.1371/journal.pone.0096662. eCollection 2014. PLoS One. 2014. PMID: 24819371 Free PMC article.
-
A 10-year Review of the Clinical Presentation and Treatment Outcome of Asherman's Syndrome at a Center with Limited Resources.Ann Med Health Sci Res. 2015 Nov-Dec;5(6):442-6. doi: 10.4103/2141-9248.177984. Ann Med Health Sci Res. 2015. PMID: 27057384 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources